Blood Test for Aggressive Prostate Cancer Now Part of EAU Guidelines for PC Care

Blood Test for Aggressive Prostate Cancer Now Part of EAU Guidelines for PC Care
OPKO Health, Inc., announced that its 4Kscore Test for aggressive prostate cancer (PC) was chosen by an expert panel of the European Association of Urology (EAU) to be included in the 2016 EAU Guidelines for Prostate Cancer. The panel decided that 4Kscore, a blood test, showed greater specificity than the prostate-specific antigen (PSA) test in determining the probability of high-grade prostate cancer, and its use was indicated prior to a first biopsy or after a negative biopsy. “The EAU Prostate Cancer Guidelines Panel is an international, multi-disciplinary group of specialists in prostate cancer diagnosis and treatment,” Dr. Alberto Briganti, with the Department of Urology at San Raffaele Scientific Institute in Milan, Italy, said in a press release. “The decision to include the 4Kscore in the guidelines indicates that the Panel views the 4Kscore Test as having achieved an appropriate level of clinical evidence to recommend its use for both assessments of asymptomatic men prior to a first prostate biopsy and as an additional investigational test to be done after a negative prostate biopsy.” The 4Kscore test identifying a patient’s risk for aggressive PC — the most life-threatening form of the disease — works by using a proprietary algorithm that includes the blood levels of four separate prostat
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *